Skip to content
‹ Back to IndustriesHealthcare

How Different Materials Are Forming the Future of 3D Printing

Hobbyists and artists have utilized a wide variety of materials in their 3D printing experimentation, from ceramics to even sugar and sand.[1] The tight control and consistency that 3D printing offers users has so far encouraged experimentation in numerous sectors. As 3D printing begins to disrupt commercial industries such as construction, a select few materials…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Hobbyists and artists have utilized a wide variety of materials in their 3D printing experimentation, from ceramics to even sugar and sand.[1] The tight control and consistency that 3D printing offers users has so far encouraged experimentation in numerous sectors. As 3D printing begins to disrupt commercial industries such as construction, a select few materials have emerged as reliable, flexible, and cost-effective.

3D printing has numerous uses at nearly every stage of the construction process. Among the earliest adopters of 3D printing tech relied on it for detailed, complex, and entirely three-dimensional prototype models that used most of the same materials the final product would.[2] This “additive manufacturing” (AM) evolved to allow for onsite printing, slashing labor costs and safety concerns.[3] These demonstrations have rapidly driven up the frequency of 3D printing applications in fields like healthcare and aircraft manufacturing as well as construction. So far, metals, plastics, and ceramics have come to dominate these emerging materials markets.

Plastics and polymers are among the most widely used materials for creating small prototypes to printing affordable housing in developing countries. Acrylonitrile Butadiene Styrene (ABS), Polylactic Acid (PLA), and the polyamides PA11/PA12 are the foremost polymers being pushed by European firms such as France’s Arkema SA and Germany’s Evonik AG.[4] A specialized form of concrete that requires a supersize printer will set as it’s being printed and, due to its composite nature, is much more supportive than conventional materials.[5]

An important aspect of this burgeoning market is less the type of material itself and more the form it takes. Powder-based AM calls for powder forms of metals like titanium as well as plastics like ABS and PLA. New patents for the creation of these powders are pending while manufacturers expand their capacity to keep up with growing global demand.[6] New materials like thermoplastic filaments, resins that are photosensitive, and more are in development now, with a whole new set of applications likely to emerge.

Though the 3D printing artists of the world may not be the ones to build new homes, their experimental instincts have no doubt influenced manufacturers to follow suit. 3D printing remains a nascent technology with significant room for growth.

For the latest news, videos, and podcasts in the AEC Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @AECMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

[1] https://architizer.com/blog/inspiration/industry/data-clay/

[2] https://3dprintingindustry.com/news/top-10-3d-printed-construction-innovations-83578/

[3] https://www.researchgate.net/publication/303749537_Processing_and_properties_of_construction_materials_for_3D_printing

[4] https://blog.marketresearch.com/5-key-trends-in-3d-printing-materials

[5] https://www.forbes.com/sites/sap/2018/08/20/how-3d-printing-is-disrupting-the-materials-building-industry/#d1b131c1fdc7

[6] https://www.idtechex.com/research/reports/3d-printing-materials-2018-2028-technology-and-market-analysis-000583.asp

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

AI cuts cardiologists' echocardiogram review time by 46%

AI cuts cardiologists' echocardiogram review time by 46%

Late-breaking research presented November 9 at the American Heart Association's Scientific Sessions 2026 reported that AI-drafted preliminary echocardiogram reports were comparable to human drafts. Cardiologists averaged 4.6 minutes finalizing AI drafts versus 8.5 minutes without AI. The findings are a non-peer-reviewed abstract.

  • 01Cardiologists averaged 4.6 minutes finalizing AI-drafted echo reports versus 8.5 minutes without AI, about 46% less time.
  • 02Cardiologists made substantial changes to 50.6% of AI drafts and 49.7% of human drafts.
  • 03The research used 1,200 echocardiograms from 21 Kaiser Permanente Northern California medical centers.

Nov 9, 2026

Hospitals can meet antibiotic stewardship rules without a full-time ID hire

Hospitals can meet antibiotic stewardship rules without a full-time ID hire

Access TeleCare pharmacist Ashley Selby describes a telehealth antimicrobial stewardship model sized to each hospital's gaps. Joint Commission Standard MM.09.01.01 and 42 CFR 482.42 require a qualified physician and/or pharmacist leader, not a full-time hire, and a 14-study meta-analysis found telehealth stewardship cut antibiotic days of therapy without changing mortality.

  • 01Joint Commission Standard MM.09.01.01, in force since January 2023, requires a physician and/or pharmacist qualified in infectious diseases or stewardship to lead the program, and its committee note allows remote participation.
  • 02The Board of Pharmacy Specialties counts more than 2,380 BCIDP pharmacists nationally, while many small hospitals still assign stewardship to pharmacists without ID training.
  • 03A 14-study meta-analysis found telehealth stewardship raised guideline adherence and cut antibiotic days of therapy, but did not significantly change mortality.

Nov 9, 2026

Caris launches blood-based treatment response monitoring as Q3 revenue rises 27%

Caris launches blood-based treatment response monitoring as Q3 revenue rises 27%

Caris Life Sciences completed approximately 61,500 clinical cases in Q3 2026 and raised 2026 revenue guidance to $1.04-$1.05 billion. Caris Assure is now available for therapeutic response monitoring, and Caris Confirm, a minimal residual disease assay, is targeted to launch before year-end.

  • 01Caris said higher operating expenses were driven primarily by headcount-related costs, research and development investment and marketing.
  • 02Caris Assure is now available for therapeutic response monitoring, and Caris Confirm, a whole genome, tumor-informed assay for minimal residual disease, is targeted to launch before year-end.
  • 03Caris reaffirms its guidance for clinical therapy selection volume growth of approximately 20%.

Nov 8, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512